MEDTECH Reports Revenue Growth of 81% to €3.1 Million for Fiscal Third Quarter 2015/16

Life Science Investing News

MEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing surgical robots, has today announced its revenue for the fiscal third quarter of 2016 (3 months ended March 31, 2016). According to the news: Steady growth momentum throughout Q3 During the 3rd quarter of the 2015/16 fiscal period, Medtech continued to expand …

MEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing surgical robots, has today announced its revenue for the fiscal third quarter of 2016 (3 months ended March 31, 2016).
According to the news:

Steady growth momentum throughout Q3

During the 3rd quarter of the 2015/16 fiscal period, Medtech continued to expand with steady progress in revenue of €3.1 million, up 81% compared with the same period in the prior year. With the sale of 10 new ROSA™ systems during the quarter (7 in the United States, 2 in China and 1 in France), Medtech has pursued its strategy to increase market share. Furthermore, this quarter Medtech recorded the first sale of its ROSA™ Spine robot in the United States, following FDA clearance in January 2016.

Click here to view the full press release. 

The Conversation (0)
×